News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
761,871 Results
Type
Article (49239)
Company Profile (374)
Press Release (712244)
Multimedia
Podcasts (124)
Webinars (20)
Section
Business (214446)
Career Advice (2199)
Deals (36925)
Drug Delivery (124)
Drug Development (84460)
Employer Resources (180)
FDA (17184)
Job Trends (15555)
News (361856)
Policy (34067)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2817)
Academic (1)
Accelerated approval (33)
Adcomms (29)
Allergies (144)
Alliances (53353)
ALS (174)
Alzheimer's disease (1737)
Antibody-drug conjugate (ADC) (337)
Approvals (17422)
Artificial intelligence (562)
Autoimmune disease (155)
Automation (38)
Bankruptcy (372)
Best Places to Work (12028)
BIOSECURE Act (21)
Biosimilars (194)
Biotechnology (253)
Bladder cancer (161)
Brain cancer (63)
Breast cancer (658)
Cancer (4968)
Cardiovascular disease (423)
Career advice (1858)
Career pathing (37)
CAR-T (296)
CDC (47)
Celiac Disease (2)
Cell therapy (782)
Cervical cancer (36)
Clinical research (71666)
Collaboration (1793)
Company closure (4)
Compensation (1162)
Complete response letters (59)
COVID-19 (2858)
CRISPR (98)
C-suite (858)
Cystic fibrosis (150)
Data (6282)
Decentralized trials (2)
Denatured (45)
Depression (139)
Diabetes (506)
Diagnostics (7031)
Digital health (46)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (269)
Drug pricing (200)
Drug shortages (30)
Duchenne muscular dystrophy (233)
Earnings (92268)
Editorial (60)
Employer branding (22)
Employer resources (158)
Events (123802)
Executive appointments (1006)
FDA (20348)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1529)
Gene editing (215)
Generative AI (50)
Gene therapy (631)
GLP-1 (1021)
Government (4849)
Grass and pollen (7)
Guidances (386)
Healthcare (19790)
HIV (59)
Huntington's disease (46)
IgA nephropathy (83)
Immunology and inflammation (276)
Immuno-oncology (59)
Indications (104)
Infectious disease (3129)
Inflammatory bowel disease (199)
Inflation Reduction Act (14)
Influenza (115)
Intellectual property (251)
Interviews (341)
IPO (17126)
IRA (52)
Job creations (3885)
Job search strategy (1553)
JPM (63)
Kidney cancer (16)
Labor market (86)
Layoffs (588)
Leadership (33)
Legal (8239)
Liver cancer (95)
Longevity (14)
Lung cancer (663)
Lymphoma (380)
Machine learning (44)
Management (63)
Manufacturing (815)
MASH (165)
Medical device (14551)
Medtech (14605)
Mergers & acquisitions (20867)
Metabolic disorders (1302)
Multiple sclerosis (159)
NASH (17)
Neurodegenerative disease (329)
Neuropsychiatric disorders (91)
Neuroscience (2998)
Neurotech (1)
NextGen: Class of 2026 (6953)
Non-profit (4721)
Now hiring (65)
Obesity (614)
Opinion (283)
Ovarian cancer (167)
Pain (205)
Pancreatic cancer (231)
Parkinson's disease (292)
Partnered (34)
Patents (503)
Patient recruitment (491)
Peanut (58)
People (61669)
Pharmaceutical (73)
Pharmacy benefit managers (30)
Phase 1 (22634)
Phase 2 (31473)
Phase 3 (23330)
Pipeline (5181)
Policy (296)
Postmarket research (2639)
Preclinical (9735)
Press Release (71)
Prostate cancer (245)
Psychedelics (49)
Radiopharmaceuticals (300)
Rare diseases (874)
Real estate (6335)
Recruiting (71)
Regulatory (25460)
Reports (52)
Research institute (2607)
Resumes & cover letters (388)
Rett syndrome (27)
RNA editing (20)
RSV (79)
Schizophrenia (151)
Series A (256)
Series B (192)
Service/supplier (14)
Sickle cell disease (103)
Special edition (23)
Spinal muscular atrophy (166)
Sponsored (43)
Startups (3950)
State (2)
Stomach cancer (20)
Supply chain (106)
Tariffs (90)
The Weekly (77)
Vaccines (1054)
Venture capital (94)
Weight loss (406)
Women's health (88)
Worklife (19)
Date
Last 7 days (612)
Last 30 days (2023)
Last 365 days (30964)
2026 (2930)
2025 (31438)
2024 (36712)
2023 (41608)
2022 (52879)
2021 (57494)
2020 (56091)
2019 (48936)
2018 (36877)
2017 (34014)
2016 (33707)
2015 (39879)
2014 (33488)
2013 (28735)
2012 (30885)
2011 (31466)
2010 (29394)
Location
Africa (804)
Alabama (86)
Alaska (7)
Arizona (317)
Arkansas (14)
Asia (42775)
Australia (7156)
California (11482)
Canada (3287)
China (1140)
Colorado (485)
Connecticut (493)
Delaware (344)
Europe (94960)
Florida (1680)
Georgia (367)
Hawaii (3)
Idaho (64)
Illinois (887)
India (65)
Indiana (525)
Iowa (23)
Japan (430)
Kansas (131)
Kentucky (40)
Louisiana (28)
Maine (72)
Maryland (1406)
Massachusetts (8359)
Michigan (345)
Minnesota (643)
Mississippi (6)
Missouri (137)
Montana (34)
Nebraska (28)
Nevada (124)
New Hampshire (85)
New Jersey (3025)
New Mexico (32)
New York (3007)
North Carolina (1498)
North Dakota (10)
Northern California (5554)
Ohio (341)
Oklahoma (22)
Oregon (47)
Pennsylvania (2306)
Puerto Rico (23)
Rhode Island (48)
South America (1185)
South Carolina (66)
South Dakota (1)
Southern California (4476)
Tennessee (175)
Texas (1777)
United States (40851)
Utah (344)
Vermont (1)
Virginia (267)
Washington D.C. (82)
Washington State (943)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
761,871 Results for "molecular targeting technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SEED Therapeutics Doses First Patient in Phase 1 Trial of ST-01156, a Molecular Glue Degrader Targeting RBM39
January 12, 2026
·
3 min read
Press Releases
Microbix Presents Molecular Pathology Platform Results
February 4, 2026
·
5 min read
Press Releases
Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology
December 30, 2025
·
4 min read
Press Releases
OncoNano Medicine Announces Presentation at AACR-NIC-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2025
·
1 min read
Press Releases
Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital Upsized and over-subscribed Series A total funding of $44 million secured Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging disease targets
September 4, 2025
·
1 min read
Press Releases
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
October 15, 2025
·
4 min read
Press Releases
BrYet US, Inc. Expands Patent Portfolio with New U.S. Patent for Targeted Drug Delivery
Near-term applications include combinations with kinase inhibitors (KIs) that achieve enhanced concentration at target sites and synergistic delivery of multiple KIs to the same location
November 13, 2025
·
1 min read
Press Releases
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
·
1 min read
Press Releases
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 27, 2025
·
4 min read
Press Releases
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 28, 2025
·
7 min read
1 of 76,188
Next
